AnaptysBio - Home
About
Overview
Strategy
Senior Leadership
Board of Directors
Scientific Advisory Board
Contact
Technology
Therapeutic Antibodies
Somatic Hypermutation
SHM Platform
Key Advantages
Publications
Pipeline
Overview
Rosnilimab
ANB032
Imsidolimab
ANB033
Partnerships
Investors / News
Overview
News
Events
Presentations
Goverance
Stock Information
Analyst Coverage
SEC Filings
Investor FAQs
Contact
Careers
Overview
Job Openings
Health and Financial Benefits Overview
Contact
Toggle
Therapeutic Antibodies
for Severe Disease
Therapeutic Antibodies
for Severe Disease
Therapeutic Antibodies
for Severe Disease
December 2, 2022
AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer
AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer
November 21, 2022
AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference
AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference
November 14, 2022
AnaptysBio Recognized in BioSpace’s 2023 Best Places to Work
AnaptysBio Recognized in BioSpace’s 2023 Best Places to Work
About
Technology
Pipeline
Investors
Careers
